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that are essential for the assembly of the cata-
lytic core of cytochrome c oxidase (COX). Here
we show that they have additional, unexpected
roles in cellular copper homeostasis. Mutations
in either SCO result in a cellular copper defi-
ciency that is both tissue and allele specific.
This phenotype can be dissociated from the
defects in COX assembly and is suppressed by
overexpression of SCO2, but not SCO1. Over-
expression of a SCO1 mutant in control cells
in which wild-type SCO1 levels were reduced
by shRNA recapitulates the copper-deficiency
phenotype in SCO1 patient cells. The copper-
deficiency phenotype reflects not a change in
high-affinity copper uptake but rather a propor-
tional increase in copper efflux. These results
suggest amitochondrial pathway for the regula-
tion of cellular copper content that involves sig-
naling through SCO1 and SCO2, perhaps by
their thiol redox or metal-binding state.
INTRODUCTION
Copper is an essential micronutrient required by proteins
that function in a wide range of metabolic pathways, in-
cluding mitochondrial respiration, free radical scavenging,
and neurotransmitter biosynthesis (Hamza and Gitlin,
2002). Its properties as a transition metal, however, allow
copper to generate potentially cytotoxic free radicals when
free within the cell. Cellular mechanisms have therefore
evolved to ensure that copper is safely delivered to dis-
crete subcellular locations by specific chaperones foreither storage or incorporation into target molecules (Rees
and Thiele, 2004; Tao and Gitlin, 2003). Accordingly, there
is essentially no free copper in the cytoplasm under nor-
mal physiological conditions (Rae et al., 1999).
Two cuproproteins, Cu/Zn superoxide dismutase (SOD1)
and cytochrome c oxidase (COX), are metallated in the
mitochondrial intermembrane space; however, the cellular
chaperones that deliver copper to mitochondria have yet
to be identified. In higher eukaryotes, COX is composed
of 13 structural subunits that are encoded in both the
nuclear and mitochondrial genomes. Highly conserved
domains within two of the mitochondrially encoded sub-
units (I and II) of COX contain copper centers (CuA and
CuB) that are essential for enzyme catalysis. Metallation
of these sites occurs during assembly of the holoenzyme
complex and is dependent, at least in part, on a bioactive
pool of copper within the mitochondrial matrix (Cobine
et al., 2004, 2006a).
Several accessory factors that are essential for copper
delivery to COX have been identified (reviewed in Cobine
et al., 2006c), and pathogenic mutations in two of these,
SCO1 and SCO2, have thus far been described (Jaksch
et al., 2000; Papadopoulou et al., 1999; Valnot et al.,
2000). Patients present with early-onset, tissue-specific
clinical phenotypes with fatal outcomes as a result of a
severe, isolated COX deficiency; however, SCO2 muta-
tions are associated primarily with neonatal encephalo-
cardiomyopathy, while mutations in SCO1 cause a neo-
natal hepatopathy and ketoacidotic coma. The distinct
clinical phenotypes are not a result of tissue-specific
expression of the two genes, as SCO1 and SCO2 are
ubiquitously expressed and exhibit a similar expression
pattern in different human tissues (Papadopoulou et al.,
1999). All reportedSCO2 patients carry at least one E140K
missense allele. Patients homozygous for the E140K
mutation have a delayed onset of the disease pathology
and a more prolonged course of disease as comparedCell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc. 9
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Human SCO Proteins Regulate Copper Homeostasisto compound heterozygotes (Jaksch et al., 2001a). SCO1
mutations have only been reported in a single pedigree
(Valnot et al., 2000) in which affected individuals were
compound heterozygotes, with a nonsense mutation on
one allele and a P174L missense mutation on the second
allele.
Molecular genetic and biochemical analyses of SCO1
and SCO2 patient cell lines have demonstrated that
human SCOs have essential, nonoverlapping functions
in the biogenesis of the CuA site that depend on their
ability to bind both Cu(I) and Cu(II) (Horng et al., 2005;
Leary et al., 2004). Their precise molecular function,
however, remains unknown and underscores one of the
most puzzling questions in the field—namely, how do
mutations in ubiquitously expressed housekeeping genes
give rise to tissue-specific clinical phenotypes? Here
we demonstrate that mutations in SCO1 and SCO2 pro-
duce significant reductions in cellular copper content
that are both tissue and allele specific, suggesting a mito-
chondrial pathway for the regulation of cellular copper
homeostasis.
RESULTS
Tissue-Specific Differences in COX Deficiency
in SCO1 and SCO2 Patients
To investigate the molecular genetic basis of the tissue-
specific COX deficiencies in SCO patients, we first
assessed COX assembly in mitochondria isolated from
the liver, heart, and skeletal muscle of SCO1 and SCO2
patients and age-matched controls by blue native PAGE
(BN-PAGE) analysis. In SCO2 patients, COX was almost
undetectable in heart and skeletal muscle; however, the
amount of fully assembled holoenzyme in liver was com-
parable to that in controls (Figure 1A), consistent with a
recent report (Stiburek et al., 2005). In contrast, both liver
and skeletal muscle from the SCO1 patient exhibited a
severe deficiency in COX assembly.
Immunoblot analysis of the steady-state levels of the
mutant SCO proteins showed that levels of SCO1 P174L
were only slightly reduced in skeletal muscle and were in
the control range in liver (Figure 1B), consistent with the
expression of a single, stable missense allele. In contrast,
SCO2 patient tissues exhibited a drastic reduction in the
amount of mutant SCO2 in skeletal muscle, liver (Fig-
ure 1B), and heart (data not shown). The relatively normal
assembly of COX in the liver of SCO2 patients is not there-
fore simply a function of higher residual levels of mutant
SCO2 protein, which appears unstable in all tissues. Fur-
thermore, it could not be attributed to a compensatory
upregulation of other factors (SCO1, COX11, and COX17)
involved in mitochondrial copper delivery to COX (Figures
1B and 1C; Leary et al., 2004).
Striking differences in SCO2 content were, however,
observed among control tissues (Figure 1B). By analyzing
incremental amounts of mitochondrial protein from heart,
skeletal muscle, and liver of a representative control, we
estimate that the SCO2 content of control liver is 3- to
5-fold higher than in heart or skeletal muscle (Figure 1D).10 Cell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc.This compares with a mitochondrial COX content of
300 U/mg in liver versus 1350 U/mg in heart, suggesting
that SCO2 may have other functions in the liver in addition
to COX assembly. The above data show that the severity
of the COX assembly defect in SCO patient tissues is
consistent with the observed clinical phenotypes, but they
do not explain why COX assembly is severely affected in
the heart and skeletal muscle of SCO2 patients but not
in the liver.
Mutations in SCO1 and SCO2 Produce a Severe
Copper Deficiency in Affected Tissues
Several studies have shown rescue of the COX deficiency
in SCO2 fibroblasts and myoblasts and its partial rescue
in SCO1 fibroblasts following supplementation of culture
media with copper salts (Jaksch et al., 2001b; Leary
et al., 2004; Salviati et al., 2002). Reversal of the hyper-
trophic cardiomyopathy in a SCO2 patient has also been
reported following administration of copper histidine (Cu-
His) (Freisinger et al., 2004). These observations raise the
possibility that alterations in tissue copper content could
be responsible for tissue-specific differences in the sever-
ity of COX deficiency in SCO patients. To test this hypo-
thesis, we measured the total cellular copper content in
skeletal muscle, heart, and liver from SCO patients and
controls (Figure 2 and data not shown). In the normal liver,
copper content declines rapidly during early development
from several hundred mg/g dry weight in neonates to
a mean of 18.6 ± 3.9 mg/g dry weight beyond 6 months
of age (Figure 2A, n = 38), whereas copper levels do not
change significantly with age in either skeletal muscle
(7.6 ± 1.0 mg/g, n = 23) or heart (8.7 ± 0.5 mg/g, n = 9) (Fig-
ures 2B and 2C). The SCO1 patient exhibited a severe
copper deficiency in both liver and skeletal muscle (33
and 1.7 mg/g dry weight, respectively), with copper con-
tent being well below the lowest level measured in age-
matched controls (Figures 2A and 2C). Mutations in
SCO2 also resulted in a severe reduction in the copper
content of patient heart to about 25% of the mean control
value (Figure 2B). Changes in skeletal muscle copper con-
tent in SCO2 patients were more variable: 2 of 4 patients
were on the low end of the normal range, one was severely
deficient, and one was in the normal range (Figure 2C). The
copper content in SCO2 patient liver was on the low end
of the normal range (Figure 2A); however, it was about
16-fold higher than the mean value observed in patient
skeletal muscle (92.3 versus 5.6 mg/g dry weight) and
40-fold higher than the value observed in patient heart.
This copper level is also about 2-fold greater than that
found in SCO2 fibroblasts treated chronically with 300 mM
Cu-His (data not shown), which results in a full rescue of
the COX deficiency (Jaksch et al., 2001b). We conclude
that mutations in SCO1 or SCO2 can produce severe, tis-
sue-specific reductions in total cellular copper levels
that would serve to exacerbate the severity of the COX
deficiency. Of the tissues we were able to analyze, only
the liver of SCO2 patients appears to contain sufficient
copper to promote SCO2-independent COX assembly in
neonatal life.
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Human SCO Proteins Regulate Copper HomeostasisFigure 1. Tissue-Specific COX Assembly Defects in SCO1 and SCO2 Patients
(A) Mitochondrial extracts (5 mg) from control, SCO1, and SCO2 patient heart, skeletal muscle, and liver were fractionated on BN-PAGE gels, and
membranes were blotted with antibodies specific to individual structural subunits of complex I (anti-39 kDa), complex III (anti-core 1), and COX
(anti-COX IV). SCO2-1 and SCO2-2 are affected siblings (E140K/L151P) and are unrelated to SCO2-3 (E140K/R171W).
(B) Mitochondrial extracts (15 mg) from control, SCO1, and SCO2 patient skeletal muscle and liver were fractionated on 15% acrylamide gels under
denaturing conditions, and membranes were blotted with polyclonal antisera to detect SCO1, SCO2, and COX11. Core 1, SDH70, and porin served
as internal loading controls. Exposure times for the visualization of all proteins were identical in both liver and skeletal muscle, allowing for direct
comparison of differences in their abundance between the two tissues. The asterisk beside the upper panel for skeletal muscle highlights the longer
exposure time that is necessary to visualize SCO2 in all of the controls.
(C) Protein extracts were prepared and analyzed exactly as described in (B), except that, due to limiting amounts ofSCO2 patient heart sample, a total
of only 3.5 mg protein was loaded per lane.
(D) Incremental amounts of mitochondrial protein (1–10 mg) from heart, skeletal muscle, and liver from a representative control were analyzed as
described in (B).Cell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc. 11
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from Patients with Other COX Assembly Defects
To validate and extend the results obtained from tissue
copper measurements, we measured total cellular copper
content in fibroblast lines derived from all of our patients
with mutations in COX assembly factors. Consistent with
the tissue analyses,SCO1 patient fibroblasts exhibited the
most severe copper-deficiency phenotype of all patient
Figure 2. Mutations in SCO1 and SCO2 Produce Cellular
Copper-Deficiency Phenotypes in Affected Tissues
Copper levels were measured in control, SCO1, and SCO2 patient tis-
sues by ICP-MS or ICP-OES and are expressed as a function of tissue
dry weight. In both patient backgrounds, the levels of zinc and iron
were within the control range (data not shown). Mutations in the
SCO2 patients included E140K/R171W (skeletal muscle), E140K/
L151P (liver), E140K/C133S (liver and heart), E140K/R90X (skeletal
muscle), and E140K/E140K (skeletal muscle [n = 2]).12 Cell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc.backgrounds (Figure 3A). Analysis of severalSCO2 patient
cell lines also revealed a clear genotype-phenotype corre-
lation with respect to cellular copper deficiency: patients
carrying two missense alleles were on the low end of the
normal range, while those carrying a single missense allele
were severely copper deficient (% of maximum control:
46.2 ± 3.7 versus 17.7 ± 4.3 respectively, n = 3 for each
group). Reduced cellular copper levels in both SCO1
and SCO2 patient backgrounds were further supported
Figure 3. Mutations in a Number of COX Assembly Factors
Produce a Cellular Copper-Deficiency Phenotype in Patient
Fibroblasts that Is Suppressed by Overexpression of SCO2
(A) Copper content was quantified in cell pellets from control and
patient (SCO1, SCO2, COX10, COX15, and SURF1) fibroblasts by
ICP-OES. A fraction of the total cellular material was also used to mea-
sure COX and citrate synthase (CS) enzyme activities. Both COX activ-
ity and cellular copper content were expressed as a percentage of the
maximum control value after normalization to CS activity or total cellu-
lar zinc levels. Expressing cellular copper levels as a function of either
dry weight or total cellular sulfur content did not influence the results.
SCO2 patients carrying a single missense allele are denoted by an
asterisk.
(B) Control andCOX15patient fibroblasts were transduced with cDNAs
expressing SCO1, SCO2, or SCO1 and SCO2. Following positive drug
selection, copper levels in these cells were compared with those in
untransduced cells. The percentage of maximum control values for
both COX activity and cellular copper content were calculated for
baseline cells and for cells in which each construct or group of con-
structs was overexpressed (mean ± SEM, n = 2–4 for total number of
controls per group; n = 5 for COX15 baseline cells).
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Human SCO Proteins Regulate Copper HomeostasisTable 1. Cellular Copper Levels and COX Activity in Control, SCO1, and SCO2 Patient Fibroblasts
Cell Line
Baseline SCO1a SCO2b SCO1/SCO2a SCO1 P174La SCO2 E140Kc
Copper COX Copper COX Copper COX Copper COX Copper COX Copper COX
Controls 67.1 ± 3.9 88.6 ± 2.1 79.4 ± 13.5 90.0 ± 7.3 78.5 ± 5.8 95.2 ± 3.3 75.2 ± 9.8 96.2 ± 3.1 64.6 ± 11.0 85.8 ± 4.4 86.1 ± 8.5 91.7 ± 4.8
SCO2 40.6 ± 6.9 51.7 ± 1.6 40.0 21.3 65.3 ± 10.3 89.0 ± 5.1 32.0 17.7 46.9 33.9 ± 2.9 44.0 ± 9.6 86.6 ± 8.2
SCO1 11.3 ± 3.0 16.9 ± 6.4 14.0 100.0 34.1 ± 5.8 4.9 ± 1.9 36.0 9.5 14.6 36.6 ± 4.8 24.5 1.8
COX activity was normalized to citrate synthase activity, and cellular copper content was expressed as a function of total cellular
zinc levels (mean ± SEM, wherever applicable). Expressing cellular copper levels as a function of either dry weight or total cellular
sulfur content did not influence the results. All values are expressed as a percentage of the maximum control value within a given
group. Baseline measurements of COX activity and copper content were made in both primary and immortalized fibroblasts. Al-
though copper levels were higher in immortalized cells from both control and patient fibroblasts, the ratio of copper to zinc and
the relationship between copper levels in controls and patients remained constant. Cellular copper content was therefore ex-
pressed as a function of zinc to allow for inclusion of all the data. Multiple measurements (n = 7, minimum) were made in baseline
cells (6 controls, 4SCO2 patients [two missense alleles, n = 3; one missense allele, n = 1], and 1 SCO1 patient). In all overexpression
experiments, single measurements of COX activity and copper levels were made in 4 controls.
a 2 SCO2 patients (n = 1 for one and two missense alleles), SCO1 patient (n = 1).
b 6 SCO2 patients (n = 3 for each group), SCO1 patient (n = 3).
c 6 SCO2 patients (n = 3 for each group), SCO1 patient (n = 2).by the diminished activity of SOD1, another cellular pro-
tein that requires copper for catalytic activity (SCO1
patient, 51.3 ± 6.4 [n = 7]; SCO2 patients [two missense
alleles], 78.2 ± 3.3 [n = 2, 4 replicates each];SCO2 patients
[one missense allele], 55.1 ± 11.6 [n = 1, 4 replicates] % of
total cellular SOD).
Unexpectedly, fibroblast lines from COX10 and COX15
patients, whose COX deficiency results from a defect in
heme A biosynthesis, also showed reduced cellular cop-
per levels, with one of the two COX10 fibroblast lines and
both of the COX15 fibroblast lines being severely copper
deficient (Figure 3A). To test whether the copper defi-
ciency in COX15 cells could be rescued by altering SCO
levels, we overexpressed SCO1 or SCO2 alone or in com-
bination (Figure 3B). Cellular copper levels were unaffected
by overexpressing SCO1; however, the cellular copper
deficiency was rescued by overexpressing SCO2, an
effect that was attenuated when SCO1 and SCO2 were
overexpressed together. Overexpression of the SCOs had
no effect on COX activity. In contrast, overexpression of
COX15, while rescuing the COX defect, did not suppress
the copper deficiency (data not shown). These data sug-
gest that the function of a number of COX assembly factors
ties into a common signaling pathway involved in the
regulation of cellular copper homeostasis that is distinct
from the COX assembly pathway. The ability of SCO2 over-
expression to suppress the cellular copper-deficiency
phenotype further suggests that it has a prominent role in
this signaling pathway.
Dissociation of the COX Assembly Defect
from the Copper Deficiency in SCO Fibroblasts
To further define the molecular genetic basis of mito-
chondrial regulation of cellular copper homeostasis, we
focused our attention on SCO patient cell lines. We first
tested whether overexpression of cDNAs that either
restore COX activity in patient cells or act as dominantCnegatives (Leary et al., 2004) could suppress the cellular
copper-deficiency phenotype (Table 1). Overexpression of
a wild-type SCO2 cDNA restored COX activity and res-
cued the cellular copper deficiency in SCO2 patient fibro-
blasts, while cellular copper levels were unchanged by
overexpression of either full-length SCO1 or a SCO1/SCO2
chimera, both of which exert a strong dominant-negative
phenotype at the level of COX activity. In contrast, the
severe copper deficiency in SCO1 patient fibroblasts was
not suppressed by SCO1 overexpression, despite the
complete rescue of COX activity. Cellular copper levels
were partially restored, however, in SCO1 patient fibro-
blasts overexpressing either SCO2 or the SCO1/SCO2
chimera, both of which exacerbate the COX deficiency in
these cells (Table 1). These data provide further evidence
that the copper deficiency in both SCO backgrounds is
attributable not to changes in COX content per se but
rather to some additional aspect of SCO protein function
that is compromised in these patients.
The Copper-Deficiency Phenotype in SCO1 Patient
Fibroblasts Can Be Recapitulated in a Control Cell
Line
To test whether SCO1 P174L exerts its effects on cellular
copper homeostasis by acting as a dominant negative, we
overexpressed SCO1 P174L in control, SCO1, and SCO2
patient fibroblasts and measured cellular copper content
and COX activity (Table 1). While overexpression of SCO1
P174L altered COX activity in both SCO patient back-
grounds, no significant changes were observed in cellular
copper levels. Pairwise comparisons in controls also re-
vealed that cellular copper content was unaffected by
overexpressing SCO1 P174L (data not shown). These data
suggested that the manifestation of the cellular copper-
deficiency phenotype might depend on the relative levels
of wild-type to mutant SCO1. To investigate this possibil-
ity, we used an RNAi approach in a control fibroblast line inell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc. 13
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Human SCO Proteins Regulate Copper HomeostasisFigure 4. SCO1 P174L Modulates Cellular Copper Levels
(A) Immunoblot analysis of mitoplasts (20 mg) from individual clones from a control fibroblast line (P) overexpressing one of two different SCO1 shRNA
constructs (1 and 2) alone () or in combination with SCO1 P174L. Levels of SCO1 in controls (C1–C3), SCO1 patient fibroblasts, and bulk cultures
of SCO1 patient fibroblasts overexpressing one of two different SCO1 shRNA constructs are also shown. Porin served as an internal loading
control.
(B) Cellular copper levels and COX activity were measured in five control clones that showed the greatest knockdown of SCO1 protein levels with each
SCO1 shRNA construct and in bulk cultures of SCO1 patient fibroblasts overexpressing the SCO1 shRNA constructs alone (n = 6) or in combination
with a wild-type SCO1 cDNA (n = 3). Values for both parameters are expressed relative to the untransduced parental lines (mean ± SEM). Although
COX activity was not measured (nm) in control SCO1 shRNA clones overexpressing SCO1 P174L, COX II protein levels were identical to those found
in the parental line (data not shown).
(C) Immunoblots of mitoplasts (20 mg) showing representative knockdown of SCO2 protein levels in bulk cultures of two control lines overexpressing
a SCO2 shRNA construct. Blots were also probed with COX II and SCO1 antisera. Porin served as an internal loading control.
(D) COX activity and cellular copper levels were measured in control (n = 4) and SCO2 patient fibroblasts (two missense alleles, n = 3; one missense
allele, n = 2) overexpressing the SCO2 shRNA construct and are expressed relative to values in untransduced parental lines (mean ± SEM).an attempt to recapitulate the copper-deficiency pheno-
type. A number of clones from two shRNA constructs that
were targeted to the 30UTR of theSCO1mRNA exhibited a
knockdown of SCO1 protein levels to approximately 15%–
20% of that in the parental line (Figure 4A). Residual SCO1
protein content in these clones was sufficient to maintain
both total COX content and cellular copper levels; how-
ever, overexpression of the SCO1 P174L variant reduced
cellular copper content by about 50% (Figure 4B). The re-
ciprocal experiment, in which the levels of SCO1 P174L14 Cell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc.were knocked down in the SCO1 patient background,
exacerbated the COX deficiency but resulted in a 40%
increase in total cellular copper content (Figures 4A
and 4B). Overexpression of wild-type SCO1 in this genetic
context further increased cellular copper levels to 245%
of parental levels and completely rescued the COX defi-
ciency (Figure 4B). We conclude that the P174L missense
mutation abrogates an aspect of SCO1 function that is
necessary for the normal regulation of cellular copper
homeostasis.
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Levels by Overexpression of the E140K Allele
in SCO2 Fibroblasts
The cellular copper deficiency in SCO2 patients could be
the result of the marked reduction in the level of functional
SCO2 protein or the presence of low residual levels of mu-
tant SCO2 protein. To distinguish between these two pos-
sibilities, we overexpressed the common E140K variant
in control, SCO1, and SCO2 patient fibroblasts and mea-
sured COX activity and cellular copper levels (Table 1).
While SCO2 E140K overexpression rescued the COX
deficiency in SCO2 patient fibroblasts, cellular copper
levels were unchanged. Overexpression of SCO2 E140K
in SCO1 patient fibroblasts reduced COX activity to near
zero but was less effective in raising cellular copper con-
tent than wild-type SCO2 (Table 1). Taken together, these
data provide genetic evidence that, when expressed in
appreciable amounts, the common E140K SCO2 variant
can function as a COX assembly factor; however, its role
in the mitochondrial regulation of cellular copper homeo-
stasis is compromised.
To further confirm that SCO2 variants do not adversely
affect cellular copper homeostasis per se, we used RNAi
to knock down the residual levels of mutant protein in
SCO2 patient fibroblasts. Given the difficulty associated
with detecting mutant SCO2 by immunoblot analysis, we
also knocked down SCO2 in control fibroblasts to test
the efficiency of the knockdown. Two representative con-
trol lines expressing the most effective SCO2 shRNA
construct showed a decrease in SCO2 abundance of up
to 50% without any changes in the levels of SCO1 (Fig-
ure 4C). Although this led to a marked reduction in COX
II protein content and a 60% decrease in COX activity,
cellular copper levels were relatively unchanged (Fig-
ure 4D). The reduction in COX activity in SCO2 patient
fibroblasts overexpressing the SCO2 shRNA construct
was comparable to that observed in the controls, suggest-
ing a similar knockdown of mutant SCO2 protein levels;
however, this was associated with a small increase in
cellular copper content. These data further suggest that
the cellular copper deficiency in SCO2 patient fibroblasts
is mainly due to a lack of wild-type SCO2 protein as
opposed to aberrant signaling through mutant SCO2
variants.
The Copper Deficiency in SCO2 Fibroblasts Can
Be Partially Rescued by Overexpression of CTR1
To test whether the mutations in SCO1 or SCO2 were ex-
erting their effects on cellular copper content by altering
the abundance of other proteins known to be important
to copper trafficking and metabolism within the cell, we
measured the steady-state levels of CTR1, Atox1, Murr1
(COMMD), Wnd (ATP7B), and Mnk (ATP7A). No consistent
differences were observed in the levels of these factors
(Figures 5A and 5B). CTR1 maturation was, however,
altered in SCO1 patient liver, with the molecular weight of
the immunoreactive band being consistent with the pres-
ence of the unglycosylated precursor protein. Immunoblot
analysis also indicated that there was some variability inthe levels of the fully glycosylated, mature form of CTR1
in SCO1 patient fibroblasts (arrow, Figures 5B and 5D),
an observation that was further confirmed by its resistance
to cleavage with endoglycosylase H (data not shown;
Klomp et al., 2003). To evaluate whether SCO mutations
affected high-affinity copper uptake, we overexpressed
CTR1 in control, SCO1, and SCO2 patient fibroblasts (Fig-
ure 5C). Overexpression of CTR1 resulted in a partial res-
cue of the copper-deficiency phenotype in SCO2 patient
fibroblasts. Those cell lines carrying two missense alleles
were particularly responsive to the manipulation of CTR1
copy number, with cellular copper levels increasing by
79% relative to untransduced parental lines. In contrast,
cellular copper levels were unchanged in SCO1 patient
fibroblasts, despite the fact that CTR1 was clearly over-
expressed (Figure 5D).
To test whether CTR1 trafficking was compromised
as a result of the SCO1 mutation, a fully functional, myc-
tagged human CTR1 (Lee et al., 2002; Petris et al., 2003)
was overexpressed in control and SCO1 patient fibro-
blasts to visualize its cellular localization in response to
manipulation of the copper content of the culture medium.
Rapid internalization of CTR1-myc was observed in both
cell lines in response to a 15 min exposure to 100 mM
Cu-His (data not shown), suggesting that high-affinity
copper uptake by endocytosis of the transporter is not
affected in the SCO1 patient cells. This is further sup-
ported by comparable sensitivity of control, SCO1, and
SCO2 patient fibroblasts to cisplatin (data not shown), a
drug whose cytotoxicity is a function of CTR1 abundance
and its localization to the plasma membrane (Guo et al.,
2004; Ishida et al., 2002).
The Copper Deficiency in SCO1 and SCO2
Fibroblasts Results from Increased Copper Efflux
To directly investigate altered copper handling in SCO
patients, we conducted uptake and retention experiments
in fibroblasts grown in serum-free medium in the presence
of trace amounts of radioactive copper (64Cu). Initial rates
(0–10 min) of 64Cu uptake in SCO1 and SCO2 patient
fibroblasts were not significantly different when compared
to the mean value for control fibroblasts (Figure 6A).
To evaluate the effects ofSCOmutations on copper efflux,
control, SCO1, and SCO2 patient fibroblasts were in-
cubated in serum-free medium containing 64Cu for 2 hr
(t = 0), at which point cells were washed in phosphate-
buffered saline (PBS) and then chased in regular medium
for up to 12 hr. Relative to controls, both SCO1 and SCO2
patient fibroblasts exhibited an enhanced rate of copper
efflux (Figure 6B). This phenotype was most pronounced
in SCO1 patient fibroblasts, where 64Cu content was
below background levels at the end of the chase. In
SCO2 patient fibroblasts, there was a clear genotype-
phenotype correlation in the rate of 64Cu efflux; the patient
cell line carrying a single missense allele (SCO2-5) was
more severely affected than the patient cell line carrying
two missense alleles (SCO2-6). Collectively, these results
strongly suggest that SCO mutations cause cellular cop-
per deficiency through aberrant signaling that ultimatelyCell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc. 15
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Human SCO Proteins Regulate Copper HomeostasisFigure 5. The Copper Deficiency in SCO1 Patient Fibroblasts Is Not Explained by a Defect in High-Affinity Uptake
(A and B) Whole-cell extracts (10 mg) from control (C1–C3) and SCO patient tissues (A) and fibroblasts (B) were fractionated on 5%–20% gradient gels
under denaturing conditions and blotted with polyclonal antisera raised against several proteins important in cellular copper trafficking (CTR1,
COX17, Atox1, Murr1, CTR1, Mnk, and Wnd). For CTR1, the fully glycosylated, mature form of the transporter is highlighted by the arrow and the
precursor protein by the circle. Glycosylated intermediates are indicated by an asterisk. Membranes were also blotted with antibodies specific for
MnSOD, Cu/ZnSOD, porin, and SDH70. Albumin served as the loading control for samples that were boiled prior to electrophoresis, while actin
was used to normalize the loading of gels in which samples were denatured at 37C.
(C) Control,SCO1, andSCO2 patient fibroblasts were transduced with aCTR1 cDNA, and, following positive drug selection, cellular copper levels and
COX activity were measured and expressed as a percentage of maximum control values. Single measurements were made in all cell lines (controls,
n = 4;SCO2 patients, n = 3 [two missense alleles, n = 2; one missense allele, n = 1]; mean ±SEM). The SCO2 patient carrying a single missense allele is
denoted by an asterisk.
(D) Whole-cell protein extracts (20 mg) were denatured and fractionated, and membranes were blotted to detect CTR1 abundance. Representative
immunoblots are shown for control, SCO1, and SCO2 patient fibroblasts alone () and overexpressing CTR1 (+). Actin served as an internal loading
control.results in the misregulation of factors important to the re-
tention of copper within the cell.
DISCUSSION
This study demonstrates that the human COX assembly
factors SCO1 and SCO2 have additional and unexpected
regulatory roles in the maintenance of cellular copper
homeostasis. Several lines of evidence support this con-
clusion. First, affected tissues and fibroblast cell lines
from SCO1 and SCO2 patients exhibit significant reduc-
tions in total cellular copper content, and there is a clear
genotype-phenotype relationship in SCO2 fibroblast lines
between the number of missense alleles present and
cellular copper levels. Second, the copper-deficiency
phenotype can clearly be dissociated from the COX
assembly defect in both SCO1 and SCO2 fibroblast lines.16 Cell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc.Third, the reduction in cellular copper levels in fibroblasts
from a patient with mutations in COX15, another COX as-
sembly factor, can be rescued by overexpressing SCO2.
Finally, pulse-chase experiments with 64Cu show that
the cellular copper deficiency in SCO1 and SCO2 patient
cell lines results from an inability to retain 64Cu rather than
a defect in its uptake by high-affinity transporters.
We have previously shown that human SCO1 and SCO2
are copper-binding proteins (Horng et al., 2005) whose
cooperative interaction is necessary for the formation of
the CuA site on COX II, an essential step in the assembly
of the catalytic core of the holoenzyme (Leary et al.,
2004). The present study shows that their additional role
in the regulation of cellular copper homeostasis also likely
involves an interaction between the two molecules, which
does not completely overlap with their function as COX
assembly factors.
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SCO1, can suppress the cellular copper deficiency in
fibroblasts from SCO2, SCO1, and COX15 patients sug-
gests that the SCO-dependent regulation of cellular cop-
per levels depends, at least in part, on the activity of
wild-type SCO2. Cellular copper content is positively cor-
related with steady-state SCO2 protein levels in neonatal
control liver, skeletal muscle, and heart, lending support
to the idea of a causal relationship. Indeed, the compara-
tively high levels of SCO2 in neonatal liver may be neces-
sary to maintain high copper levels at this stage of devel-
opment. The demonstration that overexpression of the
SCO2 E140K mutant rescues COX assembly, but not
the copper deficiency, in SCO2 patient fibroblasts clearly
shows that the two functions of SCO2 can be dissociated
and that the instability of the mutant protein is the primary
Figure 6. The Copper Deficiency in SCO1 and SCO2 Patient
Fibroblasts Results from an Enhanced Rate of Copper Efflux
The kinetics of 64Cu uptake (A) and efflux (B) were measured in control
(mean ± SEM, n = 4), SCO2 (n = 2, from patients expressing either one
or two missense alleles), and SCO1 (mean ± SEM, n = 3) patient fibro-
blasts as described in Experimental Procedures. In all cases, 64Cu
levels were normalized for protein. In the retention experiments, the
amount of 64Cu per mg protein is expressed as a percentage of the
appropriate value at t = 0.cause of the assembly defect. The cellular copper defi-
ciency then presumably results from some aspect of
SCO2 function that is missing in the E140K mutant but
that is relatively unimportant in its cooperative interaction
with SCO1 in copper delivery to the CuA site.
How might the signal from SCO2 be transduced? SCO2
is present at wild-type levels in SCO1 patient tissues and
cells, yet they are severely copper deficient, suggesting
that an abnormal signal is generated from the SCO1
P174L mutant that cannot be modulated by normal levels
of SCO2. Consistent with this interpretation, overexpres-
sion of SCO2 only partially restores cellular copper con-
tent in SCO1 patient fibroblasts, but it completely rescues
the copper-deficiency phenotype in COX15 and SCO2
patient fibroblasts, both of which contain normal amounts
of wild-type SCO1. Furthermore, the rescue of cellular
copper levels inCOX15 patient fibroblasts overexpressing
SCO2 is attenuated if SCO1 is simultaneously over-
expressed. Together, these results argue that SCO1 sig-
naling is modified by, and acts downstream of, SCO2.
Both SCOs have a conserved CXXXC copper-binding
site, and they share an overall structural similarity to thio-
redoxin reductases (Chinenov, 2000). A recent solution
and crystal structure of the soluble domain of the copper
conformer of human SCO1 showed that the conserved
cysteines on human SCO1 can undergo thiol redox chem-
istry and suggested that oxidized SCO1 may be an inter-
mediate in the transfer of copper to the CuA site (Banci
et al., 2006). One possibility, therefore, is that the function
of SCO2 is to catalyze the oxidation of SCO1, thereby
facilitating copper transfer to its substrate. Mutant SCO2
cannot fulfill this function efficiently, and, as a conse-
quence, the proportion of reduced, copper-bound SCO1
increases, signaling a state of cellular copper overload.
The P174L mutation severely compromises the COX17-
dependent metallation of SCO1 (Cobine et al., 2006b),
and we favor the idea that the mutation stabilizes a confor-
mation mimicking the copper-bound form of the wild-type
protein, the end result being the transduction of the same
copper overload signal.
Although the exact nature of signaling mechanisms that
are disturbed by the mutant SCO proteins remains to
be determined, kinetic studies of 64Cu uptake and efflux
clearly show that reduced cellular copper levels are
caused by an inability to retain copper rather than a defect
in its high-affinity uptake and that the severity of this
defect is determined by the specific mutations in a given
patient background. A previous report suggested that
copper uptake was increased in primary fibroblasts from
SCO2 patients without a change in retention time and
that copper content was increased in primary SCO2 myo-
blasts (Jaksch et al., 2001b). In that study, the evaluation
of copper uptake and retention was based entirely on end-
point measurements, and uptake was inferred from a very
long (24 hr) pulse. In contrast, our measurements were
kinetic, and we were careful to measure initial rates to spe-
cifically evaluate high-affinity copper uptake.
The altered kinetics of copper efflux provide a mecha-
nistic explanation for the observed correlation betweenCell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc. 17
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in different SCO2 patient fibroblast lines. It also explains
why overexpression of the high-affinity copper uptake
transporter CTR1 was only effective in rescuing the cop-
per deficiency in cells with the slowest rate of copper
efflux: SCO2 cells carrying two missense alleles. A defect
in copper retention most likely reflects altered trafficking
of a copper handling protein in response to aberrant sig-
naling from mutant SCOs. Mnk is the only protein in fibro-
blasts that is known to lower abnormally high copper
levels, by cycling between the trans-Golgi network and
the plasma membrane (Hung et al., 1997; Petris et al.,
1996). We have not been able to detect gross differences
in Mnk localization by indirect immunofluorescence in
control and SCO fibroblasts cultured under basal condi-
tions or in the presence of either Cu-His or BCS (T.Y.
Tao, J.D. Gitlin, S.C.L., and E.A.S., unpublished data).
Only a small percentage of the total cellular Mnk pool,
however, is required to effect rapid changes in cellular
copper status (Pase et al., 2004), and this may escape
detection using this method.
The observation that cellular copper homeostasis is dis-
turbed in patients with COX assembly defects provides
some insight into the tissue-specific etiology of disease
progression. As the activity of COX is itself reduced in cop-
per-deficiency states (Lee et al., 2001; Nose et al., 2006;
Prohaska, 1983), lower cellular copper levels would serve
to further exacerbate the COX deficiency in patients with
existing COX assembly defects. Of the tissues that we
and others (Jaksch et al., 2001b; Papadopoulou et al.,
1999; Stiburek et al., 2005; Vesela et al., 2004) have
been able to study in SCO patients, the liver and kidney
in SCO2 patients are the only ones that maintain near
normal levels of COX assembly and activity. Although
pathological examination of the liver in SCO2 patients
has revealed some abnormalities (enlargement and con-
gestion; Papadopoulou et al., 1999), there is no indication
of liver failure in SCO2 patients, all of whom die from car-
diac insufficiency. Our results suggest that hepatic copper
content in SCO2 neonates is sufficiently high to drive COX
assembly.
The copper deficiency in patients with mutations in the
SCOs or other COX assembly factors would be predicted
to produce some of the features of nutritional copper
deficiency, the extent of which would of course depend
on the degree to which different tissues are copper defi-
cient. Nutritional copper deficiency is associated with
iron-deficiency anemia and with iron overload in the gut,
liver, and spleen (Fox, 2003). Interestingly, severe, transfu-
sion-dependent anemia has been reported in two patients
with COX10 mutations (Antonicka et al., 2003), the etiol-
ogy of which has remained obscure. It will therefore be
important to create animal models to fully investigate the
physiological relevance of SCO-dependent regulation of
cellular copper homeostasis on iron metabolism.
In conclusion, this study has uncovered roles in cellular
copper homeostasis for two metallochaperones, SCO1
and SCO2, that were previously known only to function
in the assembly of the catalytic core of COX. We suggest18 Cell Metabolism 5, 9–20, January 2007 ª2007 Elsevier Inc.a model whereby SCO2 activity modulates either the thiol
redox or metallation state of SCO1, which then acts as
a molecular signal to regulate cellular copper efflux. These
findings add two members to a growing list of bifunctional
proteins that participate in cellular copper metabolism,
including Mnk, Wnd, and XIAP (Hung et al., 1997; Mufti
et al., 2006; Petris et al., 1996). Future studies will clarify
the molecular mechanisms involved in SCO-dependent
regulation of cellular copper homeostasis.
EXPERIMENTAL PROCEDURES
Tissue Culture
Primary fibroblasts from control, SCO1 (Valnot et al., 2000), and SCO2
(Jaksch et al., 2000, 2001a; Leary et al., 2006; Sacconi et al., 2003)
patients were immortalized as previously described (Leary et al.,
2004). All cells were grown in high-glucose DMEM supplemented
with 10% fetal bovine serum at 37C in an atmosphere of 5% CO2
and were tested to ensure that they were mycoplasma free (MycoAlert,
Cambrex) prior to harvesting.
Electrophoresis and Immunoblotting
Protocols for native and denaturing gel electrophoresis have been de-
scribed elsewhere (Leary et al., 2004). Blots were decorated with
monoclonal antibodies raised against porin (Calbiochem), 39 kDa,
SDH70, COX IV, and core 1 (Molecular Probes) or polyclonal antisera
raised against MnSOD, Cu/ZnSOD (Stressgen), c-myc (Santa Cruz),
albumin (ICN), COX11, SCO1 (Leary et al., 2004), SCO2 (Jaksch
et al., 2001b), CTR1 (Nose et al., 2006), Mnk, Atox1, Murr1, and Wnd
(kind gift of J.D. Gitlin, Washington University School of Medicine).
Polyclonal antiserum was raised against His-tagged, full-length
recombinant COX17 in rabbits and then affinity purified (Pierce).
Following incubation with the relevant secondary antibody, immunore-
active proteins were detected by luminol-enhanced chemilumines-
cence (Pierce).
Elemental Analyses
Tissue samples and cell pellets were digested in 40% nitric acid by
boiling for 1 hr in capped, acid-washed tubes; diluted in ultra-pure,
metal-free water; and analyzed by either ICP-OES (PerkinElmer,
Optima 3100XL) or ICP-MS versus acid-washed blanks. Concentra-
tions were determined from a standard curve constructed with serial
dilutions of two commercially available mixed metal standards
(Optima). Blanks of nitric acid with and without ‘‘metal spikes’’ were
analyzed to ensure reproducibility.
64Cu Experiments
Cells were plated in regular medium at 50%–75% confluency in 60 mm
dishes 24 hr prior to experimentation. The following day, cells were
washed twice in room-temperature PBS and incubated in Opti-MEM
supplemented with 2 mM CuCl2 for 30 min prior to the addition of
10 mCi/ml 64Cu (Universite´ de Sherbrooke). For uptake experiments,
cells were harvested at the indicated time points by washing three
times with ice-cold PBS and lysing in PBS supplemented with 1%
Triton X-100, 0.1% SDS, and 1 mM EDTA. Cell lysates were counted
using a g counter (Canberra), corrected for 64Cu decay, and normal-
ized for protein content. Incubation of a representative plate from
each cell line in ice-cold Opti-MEM for 15 min on ice was used as
a background correction for nonspecific adherence of 64Cu to either
the plate or the cells. For retention experiments, cells were treated
as described above and incubated in 64Cu-containing Opti-MEM
for 2 hr (t = 0), at which point plates were rinsed twice with room-
temperature PBS and replenished with DMEM supplemented with
10% FBS and a 1% penicillin/streptomycin mixture (GIBCO) for up
to 12 hr. Cells were harvested and counted at various time points as
described above.
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RNAi constructs were designed using a web-based algorithm (http://
www.genscript.com/rnai.html#design). Two pairs of shRNA oligo-
nucleotides targeting different regions of the 30UTR of the SCO1






TAGGAGCCTATATACA-30. For shRNA knockdown of SCO2 mRNA,
a pair of oligonucleotides, 50-GATCTGTCAGTGGACCAAGCACGAGTT
GATATCCGCTCGTGCTTGGTCCACTGATTTTTTC-30 and 50-TCGAGA
AAAAATCAGTGGACCAAGCACGAGCGGATATCAACTCGTGCTTGGT
CCACTGACA-30, which target a sequence contained within the first
exon, were selected. Primers were allowed to self-anneal, digested
with BglII and XhoI, and ligated into a commercially available retroviral
expression vector (pSUPER, Invitrogen). SCO1 P174L and SCO2
E140K point mutants were generated using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene) (Horng et al., 2005), while wild-
type cDNAs were amplified by RT-PCR. All constructs were cloned
into retroviral expression vectors. Phoenix amphotropic cells (G. Nolan,
Stanford University) were used to transiently produce and package all
individual human cDNA constructs of interest; subsequent infection
and selection of cell lines were performed as previously described
(Leary et al., 2004). Isolated mitochondria were prepared and protein
concentration, COX, and citrate synthase activities were measured as
described previously (Leary et al., 2004).
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